Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate

Osteoporosis International

Volumn 12, Issue 4, 2001, Pages 279-288

  Watts, N B ^a   Jenkins, D K ^b   Visor, J M ^b   Casal, D C ^b   Geusens, P ^c,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Quidel Corporation   (United States)

^c HASSELT UNIVERSITY   (Belgium)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alendronate; Bone alkaline phosphatase; Bone mineral density; Bone turnover; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCIUM; PLACEBO;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE LEVEL; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE MARKER; DRUG EFFECT; ENZYME IMMUNOASSAY; FEMALE; HIP; HUMAN; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VALIDATION PROCESS;

AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; DRUG MONITORING; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0035552886     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980170117     Document Type: Article

References (38)

1. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
2. Ranomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
3. Prevention of nonvertebral fractures by alendronate: A meta-analysis
4. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
5. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
6. Dose-response relationships for alendronate treatment in osteoporotic elderly women
7. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women
8. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial
9. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
10. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
11. Changes in BMD substantially underestimate the antifracture effects of alendronate and other antiresorptive drugs
12. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
13. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis
14. Short-term variations in bone remodeling biochemical markers: Cyclical etidronate and alendronate effects compared
15. Multiple forms of human serum alkaline phosphatase: Detection and quantitation
16. Multiple forms of alkaline phosphatase in plasma of hemodialysis patients
17. The renal clearance of free and conjugated pyridinium cross-links of collagen
18. Diurnal variation of bone mineral turnover in elderly men and women
19. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum
20. Direct comparison of performance characteristics of two immunoassays for bone isoform of alkaline phosphatase in serum
21. A method of comparing the areas under receiver operating characteristic curves derived from the same cases
22. Studies of the oral bioavailability of alendronate
23. Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam study
24. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study
25. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: A prospective study
26. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study
27. Monitoring alendronate therapy in osteoporosis
28. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy
29. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial
30. Biochemical effects of calcium supplementation in postmenopausal women: Influence of dietary calcium intake
31. Biological variation in bone-derived biochemical markers in serum
32. Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability
33. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates
34. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions and discontinuation
35. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women
36. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover
37. Impact of spinal degenerative changes on the evaluation of bone mineral density with dual-energy X-ray absorptiometry (DXA)
38. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy